Skip to content
value.today

Upstream Bio, Inc.

UPB
$229 Mmarket cap on Oct 13, 2026
Compare
World rank
#15,769
Revenue
$3 M
For year ending December-2025
Net income
$-143 M
-5033.0% margin
SEC filing
Employees
75
As of March 20, 2026
SEC filing

Upstream Bio, Inc. in brief

Upstream Bio, Inc. is a listed company in the Biotechnology industry, based in Waltham, Massachusetts, USA. Its market value was $229 M on 13 October 2026, which makes it the 15,769th largest listed company in the world and the 3,070th largest in the USA on this site. In the year to December 2025 it had sales of $3 M and a net loss of $143 M. It employs about 75 people and Everett Rand Sutherland is its chief executive. Its shares trade under the symbol UPB (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Upstream Bio, Inc.

We are a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. We are developing verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin, a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. Preclinical and clinical data to date demonstrate verekitug’s highly potent inhibition of the TSLP receptor, which we believe will translate to a differentiated product profile, including improved clinical outcomes, substantially extended dosing intervals and the potential to treat a broad spectrum of patients. We have advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of severe asthma, including a long-term safety and efficacy extension study, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. We reported positive top-line results in our CRSwNP Phase 2 trial in September 2025 and positive top-line results in our severe asthma Phase 2 trial in February 2026. We initiated our Phase 2 COPD trial in July 2025. We plan to initiate dosing in Phase 3 trials in both severe asthma and CRSwNP in the first quarter of 2027, prioritizing a Phase 3 development strategy that focuses on maximizing efficacy in both indications, without biomarker restriction, with quarterly at-home administration. Our experienced team is committed to maximizing verekitug’s unique attributes to address the substantial unmet needs for patients underserved by today’s standard of care.

From the company's annual report filed with the US SEC: read the report

Upstream Bio, Inc. timeline

3 events, 2024–2025
  1. 2024
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 11 October 2024; shares registered for exchange trading on 8 October 2024.
  4. 2025
  5. 💰
    Record revenue of $3 million
    FY2025, the highest of the 3 years on record.

Events of Upstream Bio, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$104 M$209 M$313 M$418 M

World rank over time

▼ down 2,593 places since 2026
2026-08-01: #13264#13,26420262026-10-13: #15857#15,8572026

Rank in USA: #2,691 (Aug 2026) · #3,052 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
79.9×
Price / book
0.7×
Free cash flow yield
-58.4%
Net margin (TTM)
-5731.8%
Operating margin
-5626.7%
Return on equity
-48.2%
Liabilities / assets
4.0%
Revenue growth
+20.3%
R&D / revenue
4800.4%
Revenue per employee
$38 K
Profit per employee
$-1.9 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2023: revenue $2M, net income $-21M$2MFY23Fiscal year ending Dec 2024: revenue $2M, net income $-63M$2MFY24Fiscal year ending Dec 2025: revenue $3M, net income $-143M$3MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$3M+20.3%$-160M$-143M-5033.0%
Dec 2024$2M-0.4%$-78M$-63M-2650.2%
Dec 2023$2M—$-40M$-21M-863.0%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-133M$0M$-133M$-2.66—
Dec 2024$-59M$1M$-60M$-5.58—
Dec 2023$-38M$0M$-38M$-12.95—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$3M
Net income, trailing 12 months
$-164M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $1M, net income $-21M$1MDec ’24Three months to Mar 2025: revenue $1M, net income $-27M$1MMar ’25Three months to Jun 2025: revenue $1M, net income $-40M$1MJun ’25Three months to Sep 2025: revenue $1M, net income $-34M$1MSep ’25Three months to Dec 2025 (from the annual report): revenue $1M, net income $-42M$1MDec ’25Three months to Mar 2026: revenue $1M, net income $-41M$1MMar ’26Three months to Jun 2026: revenue $1M, net income $-40M$1MJun ’26Three months to Sep 2026: revenue $0M, net income $-41M$0MSep ’26

Latest quarter to Sep 2026: revenue $0M (-41.2% on a year earlier), net income $-41M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Upstream Bio, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$3 M
Operating income
$-160 M
Net income
$-143 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$354 M
Total liabilities
$14 M
Total equity
$340 M

As of December-2025

Top 100 institutional investors in Upstream Bio, Inc.#

As of Sep 30, 2026
135 institutions held 48.1 M shares (about 87.7% of the shares outstanding) on Sep 30, 2026. The ten largest hold 54.5%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Upstream Bio, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1FMR LLC8,181,586+18,689 (+0.23%)14.93%$43 MNov 10, 2026
2Orbimed Advisors LLC5,693,5890 (0.00%)10.39%$30 MNov 16, 2026
3BlackRock, Inc.3,687,310-66,048 (-1.76%)6.73%$19 MNov 13, 2026
4Decheng Capital LLC2,724,8680 (0.00%)4.97%$14 MNov 13, 2026
5Enavate Sciences GP, LLC2,459,7030 (0.00%)4.49%$13 MNov 16, 2026
6Vanguard Capital Management LLC1,959,338+82,604 (+4.40%)3.57%$10 MNov 13, 2026
7Jpmorgan Chase & Co1,458,685+446,641 (+44.13%)2.66%$8 MNov 12, 2026
8D. E. Shaw & Co., Inc.1,398,735+362,691 (+35.01%)2.55%$7 MNov 16, 2026
9Millennium Management LLC1,168,181+24,406 (+2.13%)2.13%$6 MNov 16, 2026
10Goldman Sachs Group Inc1,126,897+879,980 (+356.39%)2.06%$6 MNov 16, 2026
11Geode Capital Management, LLC972,580+41,319 (+4.44%)1.77%$5 MNov 6, 2026
12Qube Research & Technologies Ltd926,237-52,263 (-5.34%)1.69%$5 MNov 13, 2026
13SEB Asset Management AB878,4730 (0.00%)1.60%$5 MNov 4, 2026
14Woodline Partners LP831,4810 (0.00%)1.52%$4 MNov 16, 2026
15Trexquant Investment LP766,231+299,801 (+64.28%)1.40%$4 MNov 16, 2026
16Vanguard Portfolio Management LLC755,981+43,314 (+6.08%)1.38%$4 MNov 13, 2026
17State Street Corp736,488-29,835 (-3.89%)1.34%$4 MNov 12, 2026
18BNP Paribas Financial Markets730,278+218,732 (+42.76%)1.33%$4 MNov 12, 2026
19Y-Intercept (Hong Kong) Ltd642,574-50,981 (-7.35%)1.17%$3 MOct 16, 2026
20Morgan Stanley635,905+111,273 (+21.21%)1.16%$3 MNov 13, 2026
21Parkman Healthcare Partners LLC618,056-317,191 (-33.92%)1.13%$3 MNov 16, 2026
22Voleon Capital Management LP477,306+192,072 (+67.34%)0.87%$3 MNov 16, 2026
23Two Sigma Investments, LP428,190+385,865 (+911.67%)0.78%$2 MNov 16, 2026
24AQR Capital Management LLC415,734-129,135 (-23.70%)0.76%$2 MNov 16, 2026
25Dimensional Fund Advisors LP374,836-6,777 (-1.78%)0.68%$2 MNov 4, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Upstream Bio, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Point72 Asset Management, L.P.372,823-80,188 (-17.70%)0.68%$2 MNov 16, 2026
27Acadian Asset Management LLC370,395+195,285 (+111.52%)0.68%$2 MNov 9, 2026
28HRT Financial LP347,991+177,401 (+103.99%)0.63%$2 MNov 13, 2026
29Bank Of America Corp /de/345,802-45,960 (-11.73%)0.63%$2 MNov 16, 2026
30Wellington Management Group LLP342,3530 (0.00%)0.62%$2 MNov 16, 2026
31Charles Schwab Investment Management Inc338,278+75,822 (+28.89%)0.62%$2 MNov 16, 2026
32Propel Bio Management, LLC335,389-15,000 (-4.28%)0.61%$2 MNov 13, 2026
33Sphera Funds Management LTD.325,831+106,131 (+48.31%)0.59%$2 MNov 16, 2026
34Schonfeld Strategic Advisors LLC302,433+76,673 (+33.96%)0.55%$2 MNov 16, 2026
35Samsara Biocapital, LLC300,361-53,356 (-15.08%)0.55%$2 MNov 16, 2026
36Northern Trust Corp288,894-8,452 (-2.84%)0.53%$2 MNov 16, 2026
37Squarepoint Ops LLC275,746-15,158 (-5.21%)0.50%$1 MNov 9, 2026
38Vanguard Fiduciary Trust Co269,677+30,061 (+12.55%)0.49%$1 MNov 13, 2026
39XTX Topco Ltd225,453-16,893 (-6.97%)0.41%$1 MNov 16, 2026
40Jump Financial, LLC201,395-21,828 (-9.78%)0.37%$1 MNov 13, 2026
41Barclays PLC198,213+169,005 (+578.63%)0.36%$1 MNov 6, 2026
42Renaissance Technologies LLC194,700+63,400 (+48.29%)0.36%$1 MNov 12, 2026
43Arrowstreet Capital, Limited Partnership189,832-167,924 (-46.94%)0.35%$1 MNov 13, 2026
44UBS Group AG158,109-76,605 (-32.64%)0.29%$1 MNov 10, 2026
45Jacobs Levy Equity Management, Inc155,028-98,064 (-38.75%)0.28%$1 MNov 16, 2026
46Walleye Capital LLC154,727-343,763 (-68.96%)0.28%$1 MNov 13, 2026
47Marshall Wace, LLP135,771New0.25%$1 MNov 13, 2026
48Los Angeles Capital Management LLC132,805+110,420 (+493.28%)0.24%$1 MNov 12, 2026
49Quantinno Capital Management LP112,795+57,957 (+105.69%)0.21%$1 MNov 13, 2026
50EntryPoint Capital, LLC105,924-23,522 (-18.17%)0.19%$1 MNov 13, 2026
51Bank of New York Mellon Corp97,148+11,401 (+13.30%)0.18%$1 MNov 5, 2026
52Man Group plc88,782+14,959 (+20.26%)0.16%$0 MNov 16, 2026
53American Century Companies Inc87,423+9,229 (+11.80%)0.16%$0 MNov 12, 2026
54Nuveen, LLC86,987+2,217 (+2.62%)0.16%$0 MNov 10, 2026
55HSBC Holdings PLC81,500+70,707 (+655.12%)0.15%$0 MNov 16, 2026
56Invesco Ltd.72,988+19,591 (+36.69%)0.13%$0 MNov 12, 2026
57Alps Advisors Inc72,045+16,817 (+30.45%)0.13%$0 MNov 3, 2026
58Algert Global LLC69,650-48,980 (-41.29%)0.13%$0 MNov 17, 2026
59Fox Run Management, L.L.C.69,504New0.13%$0 MNov 12, 2026
60Simplify Asset Management Inc.62,1130 (0.00%)0.11%$0 MOct 27, 2026
61Gsa Capital Partners LLP61,020-8,328 (-12.01%)0.11%$0 MNov 16, 2026
62Vestcor Inc59,404New0.11%$0 MNov 12, 2026
63Citadel Advisors LLC59,042New0.11%$0 MNov 16, 2026
64ExodusPoint Capital Management, LP55,027+13,982 (+34.07%)0.10%$0 MNov 16, 2026
65Virtus Investment Advisers, LLC52,022-1,616 (-3.01%)0.09%$0 MNov 12, 2026
66Russell Investments Group, Ltd.48,130+587 (+1.23%)0.09%$0 MNov 6, 2026
67Alliancebernstein L.P.45,600-6,080 (-11.76%)0.08%$0 MNov 16, 2026
68Allspring Global Investments Holdings, LLC44,947+1,765 (+4.09%)0.08%$0 MNov 4, 2026
69Rhumbline Advisers42,445+61 (+0.14%)0.08%$0 MNov 10, 2026
70Mercer Global Advisors Inc /adv39,187+25,835 (+193.49%)0.07%$0 MNov 16, 2026
71Jane Street Group, LLC36,350+20,756 (+133.10%)0.07%$0 MNov 12, 2026
72Citigroup Inc35,733-4,606 (-11.42%)0.07%$0 MNov 4, 2026
73Entropy Technologies, LP34,366+16,824 (+95.91%)0.06%$0 MNov 13, 2026
74Strs Ohio30,600+18,600 (+155.00%)0.06%$0 MOct 30, 2026
75Deutsche Bank AG\28,891-212,556 (-88.03%)0.05%$0 MNov 6, 2026
76Canada Pension Plan Investment Board28,600+17,100 (+148.70%)0.05%$0 MNov 16, 2026
77Price T Rowe Associates Inc /MD/28,0580 (0.00%)0.05%$0 MNov 16, 2026
78Tudor Investment Corp Et Al26,755New0.05%$0 MNov 16, 2026
79Aquatic Capital Management LLC23,543New0.04%$0 MNov 16, 2026
80MetLife Investment Management, LLC21,429+577 (+2.77%)0.04%$0 MNov 16, 2026
81WINTON GROUP Ltd19,8000 (0.00%)0.04%$0 MNov 12, 2026
82Savant Capital, LLC18,164New0.03%$0 MNov 6, 2026
83Shay Capital LLC18,0000 (0.00%)0.03%$0 MNov 16, 2026
84MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.17,099+882 (+5.44%)0.03%$0 MNov 16, 2026
85Creative Planning15,456-13,027 (-45.74%)0.03%$0 MNov 2, 2026
86Axq Capital, LP14,325-12,743 (-47.08%)0.03%$0 MNov 12, 2026
87Graham Capital Management, L.P.14,137-8,371 (-37.19%)0.03%$0 MNov 16, 2026
88Aigen Investment Management, LP13,327New0.02%$0 MNov 16, 2026
89Vanguard Global Advisers, LLC13,221+162 (+1.24%)0.02%$0 MNov 13, 2026
90Verdad Advisers, LP11,550-10,260 (-47.04%)0.02%$0 MNov 16, 2026
91PDT Partners, LLC11,500New0.02%$0 MNov 16, 2026
92Manufacturers Life Insurance Company, The11,328-4,407 (-28.01%)0.02%$0 MNov 13, 2026
93Voya Investment Management LLC10,834New0.02%$0 MNov 10, 2026
94Mariner, LLC10,523-22,618 (-68.25%)0.02%$0 MNov 12, 2026
95China Universal Asset Management Co., Ltd.9,994+1,333 (+15.39%)0.02%$0 MOct 28, 2026
96Police & Firemen's Retirement System of New Jersey9,4560 (0.00%)0.02%$0 MNov 9, 2026
97Wells Fargo & Company/mn7,395-22,102 (-74.93%)0.01%$0 MNov 16, 2026
98New York State Common Retirement Fund5,2000 (0.00%)0.01%$0 MNov 17, 2026
99Arax Advisory Partners4,734+2,963 (+167.31%)0.01%$0 MNov 12, 2026
100Legal & General Group Plc3,795-8,766 (-69.79%)0.01%$0 MNov 16, 2026

All 135 institutional investors, with who bought and sold →

Mutual funds holding Upstream Bio, Inc.#

131 funds in 2 countries hold shares worth $103 M (about 27.3% of the company). Since their previous reports 61 added shares and 26 sold, selling $6 M net. By country: USA 130 ($97 M), Sweden 1 ($6 M).
Mutual funds holding Upstream Bio, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.1.44 M$10 M2.6%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Small Cap Growth FundFidelity Management & Research Company LLC1.37 M$9 M2.5%0.10%no changeJul 31, 2026
🇺🇸 Fidelity Stock Selector Small Cap FundFidelity Management & Research Company LLC1.32 M$8 M2.4%0.11%no changeJul 31, 2026
🇺🇸 Select Health Care PortfolioFidelity Management & Research Company LLC800,000$7 M1.5%0.12%no changeMay 31, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors921,063$6 M1.7%<0.01%+14%Jun 30, 2026
🇺🇸 Fidelity Series Small Cap Opportunities FundFidelity Management & Research Company LLC965,800$6 M1.8%0.13%no changeJul 31, 2026
🇸🇪 SEB LäkemedelsfondSEB Funds AB878,473$6 M1.6%0.34%no changeJun 30, 2026
🇺🇸 Fidelity Small Cap Growth K6 FundFidelity Management & Research Company LLC693,618$4 M1.3%0.10%no changeJul 31, 2026
🇺🇸 Fidelity Advisor Biotechnology FundFidelity Management & Research Company LLC691,003$4 M1.3%0.20%no changeJul 31, 2026
🇺🇸 BlackRock Health Sciences Opportunities PortfolioBlackRock Advisors, LLC341,675$3 M0.62%0.05%no changeMay 29, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.386,877$3 M0.71%<0.01%+0.9%Jun 30, 2026
🇺🇸 Fidelity Advisor Health Care FundFidelity Management & Research Company LLC400,000$3 M0.73%0.08%no changeJul 31, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC384,509$2 M0.70%<0.01%+18%Jul 31, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors338,261$2 M0.62%0.02%+19%Jun 30, 2026
🇺🇸 Select Biotechnology PortfolioFidelity Management & Research Company LLC234,657$2 M0.43%0.04%no changeMay 31, 2026
🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors256,130$2 M0.47%0.02%+20%Jun 30, 2026
🇺🇸 Vanguard Strategic Small-Cap Equity FundThe Vanguard Group, Inc.234,635$2 M0.43%0.05%+141%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC177,681$1 M0.32%<0.01%+0.4%May 31, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.168,486$1 M0.31%<0.01%+3.9%May 31, 2026
🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc.161,663$1 M0.29%<0.01%−1.6%May 31, 2026
🇺🇸 Vanguard Market Neutral FundThe Vanguard Group, Inc.168,915$1 M0.31%0.20%+41%Jun 30, 2026
🇺🇸 Strategic Advisers Fidelity U.S. Total Stock FundStrategic Advisers LLC136,560$1 M0.25%<0.01%−17%May 31, 2026
🇺🇸 VIP Health Care PortfolioFidelity Management & Research Company LLC145,000$1 M0.26%0.09%no changeJun 30, 2026
🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP150,504$1 M0.27%<0.01%+39%Jul 31, 2026
🇺🇸 Fidelity Series Small Cap Core FundFidelity Management & Research Company LLC132,200$1 M0.24%0.05%no changeJul 31, 2026
🇺🇸 Fidelity Small Cap Stock FundFidelity Management & Research Company LLC131,691$1 M0.24%0.06%no changeJul 31, 2026
🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc.72,472$1 M0.13%<0.01%+79%May 31, 2026
🇺🇸 Fidelity Fundamental Small-Mid Cap ETFFidelity Management & Research Company LLC93,712$1 M0.17%0.04%+1.6%Jul 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC64,388$1 M0.12%<0.01%no changeMay 31, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.84,939$1 M0.15%<0.01%+17%Jul 31, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust62,606$1 M0.11%0.02%−23%May 31, 2026
🇺🇸 Fidelity Small Cap Discovery FundFidelity Management & Research Company LLC75,300$0 M0.14%0.02%no changeJul 31, 2026
🇺🇸 ALPS Medical Breakthroughs ETFALPS Advisors, Inc.55,699$0 M0.10%0.29%+16%May 31, 2026
🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP73,550$0 M0.13%<0.01%+162%Jul 31, 2026
🇺🇸 Fidelity Series Small Cap Discovery FundFidelity Management & Research Company LLC69,306$0 M0.13%0.02%no changeJul 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC51,794$0 M0.09%<0.01%+4.9%May 31, 2026
🇺🇸 Fidelity Enhanced Small Cap Core ETFFidelity Management & Research Company LLC61,682$0 M0.11%<0.01%no changeJun 30, 2026
🇺🇸 BlackRock Health Sciences Term TrustBlackRock Advisors, LLC56,530$0 M0.10%0.04%no changeJun 30, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC55,900$0 M0.10%<0.01%+1.7%Jun 30, 2026
🇺🇸 JPMorgan Small Cap Value FundJ.P. Morgan Investment Management Inc.49,678$0 M0.09%0.03%−5.8%Jun 30, 2026
🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors49,639$0 M0.09%<0.01%+2.2%Jun 30, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC49,342$0 M0.09%0.02%+21%Jun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC46,924$0 M0.09%<0.01%+24%Jul 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC35,347$0 M0.06%<0.01%no changeMay 31, 2026
🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP39,624$0 M0.07%<0.01%+211%Jul 31, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC36,047$0 M0.07%<0.01%no changeJun 30, 2026
🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC33,698$0 M0.06%<0.01%+89%Jul 31, 2026
🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc.25,380$0 M0.05%0.02%+4.7%May 31, 2026
🇺🇸 BlackRock Health Sciences TrustBlackRock Advisors, LLC30,052$0 M0.05%0.04%no changeJun 30, 2026
🇺🇸 Allspring Disciplined Small Cap FundAllspring Funds Management, LLC28,913$0 M0.05%0.11%newJun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.26,407$0 M0.05%<0.01%no changeJun 30, 2026
🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC28,718$0 M0.05%<0.01%no changeJul 31, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC24,780$0 M0.05%<0.01%+39%Jun 30, 2026
🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc.20,416$0 M0.04%<0.01%no changeMay 31, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation23,300$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.20,425$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Health Sciences PortfolioPacific Life Fund Advisors LLC20,337$0 M0.04%0.04%no changeJun 30, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.21,000$0 M0.04%<0.01%newJul 31, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.18,296$0 M0.03%<0.01%+33%Jun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC17,113$0 M0.03%0.01%+67%Jun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC17,030$0 M0.03%<0.01%+68%Jun 30, 2026
🇺🇸 Strategic Advisers U.S. Total Stock FundStrategic Advisers LLC14,079$0 M0.03%<0.01%+1010%May 31, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company13,073$0 M0.02%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC17,310$0 M0.03%<0.01%no changeJul 31, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC16,828$0 M0.03%<0.01%+17%Jul 31, 2026
🇺🇸 Vanguard Growth And Income FundWellington Management Company LLP15,200$0 M0.03%<0.01%−42%Jun 30, 2026
🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC14,836$0 M0.03%<0.01%no changeJun 30, 2026
🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors12,699$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC12,553$0 M0.02%<0.01%+13%Jun 30, 2026
🇺🇸 Small Cap Value FundThe Variable Annuity Life Insurance Company10,120$0 M0.02%0.03%−13%May 31, 2026
🇺🇸 JPMorgan Small Cap Value PortfolioBrighthouse Investment Advisers, LLC12,221$0 M0.02%0.03%−14%Jun 30, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC12,184$0 M0.02%<0.01%+1.4%Jul 31, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.11,100$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Multi-Manager Small Cap Equity Strategies FundColumbia Funds Series Trust I8,875$0 M0.02%<0.01%newMay 31, 2026
🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP11,605$0 M0.02%<0.01%+395%Jul 31, 2026
🇺🇸 Fidelity MSCI Health Care Index ETFFidelity Management & Research Company LLC11,496$0 M0.02%<0.01%+3.0%Jul 31, 2026
🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors9,449$0 M0.02%<0.01%−0.7%Jun 30, 2026
🇺🇸 Dimensional US Core Equity Market ETFDimensional Fund Advisors LP10,145$0 M0.02%<0.01%no changeJul 31, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC8,389$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC7,520$0 M0.01%<0.01%+25%Jun 30, 2026
🇺🇸 U.S. Core Equity 2 PortfolioDimensional Fund Advisors LP8,066$0 M0.01%<0.01%no changeJul 31, 2026
🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC7,632$0 M0.01%<0.01%newJul 31, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS6,522$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 Avantis U.S. Small Cap Equity FundAmerican Century ETF Trust5,295$0 M<0.01%0.03%no changeMay 31, 2026
🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION5,200$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 U.S. Core Equity 1 PortfolioDimensional Fund Advisors LP6,674$0 M0.01%<0.01%newJul 31, 2026
🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC5,986$0 M0.01%<0.01%+23%Jun 30, 2026
🇺🇸 NVIT Multi-Manager Small Company FundNATIONWIDE FUND ADVISORS5,900$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP6,279$0 M0.01%<0.01%newJul 31, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.5,514$0 M0.01%<0.01%+17%Jun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.5,311$0 M<0.01%<0.01%+44%Jun 30, 2026
🇺🇸 NVIT Small Cap Value FundNATIONWIDE FUND ADVISORS5,300$0 M<0.01%0.02%newJun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC5,366$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC4,879$0 M<0.01%<0.01%+29%Jun 30, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC4,040$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.4,193$0 M<0.01%<0.01%+28%Jul 31, 2026
🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC3,809$0 M<0.01%<0.01%+190%Jun 30, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC3,666$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.2,529$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC2,959$0 M<0.01%0.01%no changeJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Upstream Bio, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$105 K
15 sales, 5 insiders
Net, 12 months
-$105 K
open market only
Insiders on file
9
since
$34.0 M-$47 K$0Oct 2024: bought $34.0 M (5 trades), sold $0 (0 trades)Oct 24Mar 2026: bought $0 (0 trades), sold $47 K (5 trades)MarJun 2026: bought $0 (0 trades), sold $31 K (5 trades)JunSep 2026: bought $0 (0 trades), sold $28 K (5 trades)Sep
Bought (open market)Sold (open market)Hover a month for the totals
Upstream Bio, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Aaron DeykinChief Medical OfficerSell-895$5.490$5 K32,302Form 4
filed Everett Rand SutherlandChief Executive Officer, DirectorSell-2,095$5.490$12 K68,717Form 4
filed Allison AmbroseGeneral CounselSell-485$5.490$3 K15,563Form 4
filed Michael GrayCFO and COOSell-853$5.490$5 K27,942Form 4
filed Adam HoughtonChief Business OfficerSell-700$5.490$4 K22,901Form 4
filed Everett Rand SutherlandChief Executive Officer, DirectorSell-2,095$6.100$13 K70,812Form 4
filed Adam HoughtonChief Business OfficerSell-700$6.100$4 K23,601Form 4
filed Allison AmbroseGeneral CounselSell-477$6.100$3 K16,048Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Upstream Bio, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
3.6 M
6.5% of shares · 2.7 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1.049-for-1 split

Fails to deliver

  • : 800 shares at $4.17
  • : 10,112 shares at $5.04
  • : 7,300 shares at $5.04
  • : 704 shares at $6.69
  • : 4,012 shares at $6.61

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Upstream Bio, Inc. scorecard#

Passes 4 of the 13 checks that could be worked out: strongest in financial health (2 of 3), weakest in valuation (1 of 5). Fiscal year 2025; market cap of Oct 13, 2026.

  • Valuation1 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median0.7×Price to book 0.7× against Biotechnology's median of 2.9×.
    • ✗Price to sales below its peers' median79.9×Price to sales 79.9× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%-58.4%Free cash flow is -58.4% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 2
    • ✓Revenue grew in the newest year20.2%Revenue up 20.2% in fiscal 2025.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-2.66 vs -5.58Diluted EPS -2.66 in fiscal 2025 against -5.58 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 2
    • ✗Profitable in the newest year-$143 MNet income -$143 M in fiscal 2025.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-35.4%-35.4% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health2 of 3
    • ✓Short-term assets cover short-term liabilities26.2×Current ratio 26.16 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✓Altman Z-score outside the distress zone8.13Z-score 8.13 (safe zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year293.6%Diluted shares up 293.6% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Upstream Bio, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Upstream Bio, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023
Income statement
Revenue2.92.42.4
Research and development1376332
General and administrative261711
Operating expenses1638042
Operating income−160−78−40
Interest and finance income17124.2
Other non-operating income (expense)171520
Income tax000
Net income including minority interests−143−63−21
Net income attributable to shareholders−143−63−21
Earnings per share, basic-2.66-5.58-12.95
Earnings per share, diluted-2.66-5.58-12.95
Shares, weighted average (basic)54143.0
Shares, weighted average (diluted)54143.0
Balance sheet
Cash and cash equivalents10232626
Short-term investments24014584
Receivables0.70.60.1
Other current assets0.7r8.17.1
Current assets352479117
Property, plant and equipment0.60.60.2
Right-of-use (leased) assets1.21.80.0
Goodwill—0—
Total assets354482117
Accounts payable2.74.02.0
Current liabilities13116.5
Lease liabilities (non-current)0.51.1—
Total liabilities14129.4
Retained earnings−334−191−128
Shareholders' equity340470−123
Total liabilities and equity354482117
Shares outstanding54543.0
Cash-flow statement
Depreciation and amortization0.20.10.1
Share-based compensation106.03.3
Cash from operating activities−133−59−38
Capital expenditure−0.2−0.5−0.1
Cash from investing activities−93−59−83
Cash from financing activities2.4419130
Change in cash−2243008.8
Report10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Upstream Bio, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Material agreement 1 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 10

Upstream Bio, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K
Bylaws or fiscal year changed8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026

H-1B hiring at Upstream Bio, Inc.#

1 labor condition applications certified in fiscal 2026 for 1 positions, at a median wage of $193 K a year.

Certified, FY2026
1
#1,950 among companies on value.today
Worker positions
1
Median wage offered
$193 K
a year, full-time
Applications filed
1
Upstream Bio, Inc.: most frequent H-1B job titles in fiscal 2026
Job titlePositionsMedian wage offered
Associate Director, Regulatory AffairsRegulatory Affairs Managers1$193 K

Where: Waltham, MA 1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Upstream Bio, Inc.

How Upstream Bio, Inc. compares in Biotechnology

  • Market cap$229 M · higher than 46% of 726
  • Revenue$3 M · higher than 32% of 647
  • Revenue growth20.3% · higher than 62% of 438
  • Price / sales79.9× · lower than 12% of 339
  • Price / book0.7× · lower than 86% of 534
  • FCF yield-58.4% · higher than 20% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Upstream Bio, Inc.🇺🇸$229 M——+20.3%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 13, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of March 20, 2026
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Upstream Bio, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Upstream Bio, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Upstream Bio, Inc.? Suggest a correction